CAMP4 Therapeutics Corporation Financing Cash Flow
CAMP4 Therapeutics Corporation (CAMP) reported Financing Cash Flow of $61.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-13
- CAMP4 Therapeutics Corporation net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $4.00K, a 94.44% decline year-over-year.
- CAMP4 Therapeutics Corporation net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $57.00K.
- CAMP4 Therapeutics Corporation net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $28.59M, a 60.88% decline year-over-year.
- CAMP4 Therapeutics Corporation net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $47.38M.
- CAMP4 Therapeutics Corporation net cash provided by (used in) financing activities for fiscal 2025 was $75.89M, a 5.90% increase from fiscal 2024.
- CAMP4 Therapeutics Corporation net cash provided by (used in) financing activities for fiscal 2024 was $71.66M, a 23707.97% increase from fiscal 2023.
- CAMP4 Therapeutics Corporation net cash provided by (used in) financing activities for fiscal 2023 was $301.00K.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $4.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $61.00K 10-Q · filed 2026-08-13 | $28.65M derived: sum of 3 quarters · filed 2026-08-13 | $76.03M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $57.00K 10-Q · filed 2026-05-07 | $28.64M derived: sum of 2 quarters · filed 2026-05-07 | $76.03M derived: sum of 3 quarters · filed 2026-05-07 | $76.10M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $28.59M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $75.97M derived: sum of 2 quarters · filed 2026-03-05 | $76.04M derived: sum of 3 quarters · filed 2026-08-13 | $75.89M 10-K · filed 2026-03-05 |
| 2025-09-30 | $47.38M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $47.46M derived: sum of 2 quarters · filed 2026-08-13 | $47.30M 10-Q · filed 2025-11-06 | $120.37M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $72.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$79.00K 10-Q · filed 2026-08-13 | $72.98M derived: sum of 3 quarters · filed 2026-08-13 | $72.60M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | -$151.00K 10-Q · filed 2026-05-07 | $72.91M derived: sum of 2 quarters · filed 2026-05-07 | $72.53M derived: sum of 3 quarters · filed 2026-05-07 | $71.71M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $73.06M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $72.68M derived: sum of 2 quarters · filed 2026-03-05 | $71.86M derived: sum of 3 quarters · filed 2026-03-05 | $71.66M 10-K · filed 2026-03-05 |
| 2024-09-30 | -$386.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$1.20M derived: sum of 2 quarters · filed 2025-11-06 | -$1.40M 10-Q · filed 2025-11-06 | -$1.46M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | -$812.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$1.01M 10-Q · filed 2025-08-14 | -$1.08M derived: sum of 3 quarters · filed 2025-08-14 | |
| 2024-03-31 | -$202.00K 10-Q · filed 2025-05-13 | -$265.00K derived: sum of 2 quarters · filed 2025-05-13 | ||
| 2023-12-31 | -$63.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $301.00K 10-K · filed 2025-03-27 | ||
| 2023-09-30 | $364.00K 10-Q · filed 2024-11-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |